ReviewNature reviews. Rheumatology2023
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.
Review in Nature reviews. Rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06646913 (Transcutaneous Electrical Nerve Stimulation in Scleroderma), which is not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transcutaneous Electrical Nerve Stimulation in Scleroderma
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Systemic sclerosis and small bowel involvement: A systematic review of diagnostic approaches and current evidence.Seminars in arthritis and rheumatism · 2026Pooled it
- The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.Rheumatology (Oxford, England) · 2025Pooled it
- Cross-Phenotype Genome-Wide Association Study on the Shared Genetic Susceptibility to Systemic Sclerosis and Primary Biliary Cholangitis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Pooled it
- 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.Advances in rheumatology (London, England) · 2024Guideline
- Gastrointestinal Disorders in Scleroderma.Gastroenterology · 2026Review
- Article
- Clinical Image: Esophageal dilation and stenosis in systemic sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Proteome-wide serology reveals immune-defined subtypes of gastrointestinal disease in systemic sclerosis.bioRxiv : the preprint server for biology · 2026Article
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- PPI-Refractory GERD in Systemic Sclerosis Is Driven by Distinct Esophageal and Gastric Motility Abnormalities.medRxiv : the preprint server for health sciences · 2026Article
- Hospital-based first diagnoses of systemic sclerosis: Defining initial clinical presentations and diagnostic pathways.Rheumatology and immunology research · 2026Article
- Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group.Journal of clinical medicine · 2026Article
- Delayed gastric emptying identifies a high-risk clinical subgroup in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- Systemic Sclerosis-Related Intestinal Pseudo-Obstruction Mimicking Mechanical Small Bowel Obstruction.Cureus · 2026Article
- Biomarker patterns across skin-lung-gut burden in systemic sclerosis.Frontiers in immunology · 2026Article
- Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".Journal of scleroderma and related disorders · 2026Article
- [S2k guidelines on diagnostics and treatment of systemic sclerosis : Full version].Zeitschrift fur Rheumatologie · 2025Review
- Oesophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Systemic sclerosis: pathogenic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- Prevalence, clinical characteristics, and hospital course of systemic sclerosis-associated pseudo-obstruction.Clinical rheumatology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Nearly all patients with systemic sclerosis (SSc) are negatively affected by dysfunction in the gastrointestinal tract, and the severity of gastrointestinal disease in SSc correlates with high mortality. The clinical complications of this dysfunction are heterogeneous and include gastro-oesophageal reflux disease, gastroparesis, small intestinal bacterial overgrowth, intestinal pseudo-obstruction, malabsorption and the requirement for total parenteral nutrition. The abnormal gastrointestinal physiology that promotes the clinical manifestations of SSc gastrointestinal disease throughout the gastrointestinal tract are diverse and present a range of therapeutic targets. Furthermore, the armamentarium of medications and non-pharmacological interventions that can benefit affected patients has substantially expanded in the past 10 years, and research is increasingly focused in this area. Here, we review the details of the gastrointestinal complications in SSc, tie physiological abnormalities to clinical manifestations, detail the roles of standard and novel therapies and lay a foundation for future investigative work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.